Speech-Language Pathologists in Ellenburg Depot, NY Accepting Medicare
2 Speech-Language Pathologists found. Showing 1 - 2
 Nakeena Sykes, M.A. CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1394 Plank Rd, Box 302, Ellenburg Depot, NY 12935 Phone: 215-970-4774 |
Mrs. Sue Lynn Phillips-leclerc, SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 5572 Route 11, Northern Adirondack Central School, Ellenburg Depot, NY 12935 Phone: 518-594-3986 |
News Archive
AFFiRiS AG - Alzheimer's vaccines generate further cash flow
AFFiRiS AG announced today significant progress in their collaboration with GlaxoSmithKline Biologicals (GSK) for the development of an active vaccination programme against Alzheimer´s disease. While the lead vaccine candidate AD02 is currently in phase II clinical testing, two additional preclinical programmes have been completed successfully. The second programme was related to alternative vaccine candidates generated by AFFiRiS´ AFFITOME® technology, including candidate AD03. Based on the promising preliminary results of this programme, GSK exercised its option for the alternative vaccine candidates which triggered a EUR 2.5 million payment to AFFiRiS. An additional EUR 1 million payment became due simultaneously for the successful completion of tests of alternative vaccine formulations.
Hygieia's DIGS automatically adjusts insulin dosage in patients with diabetes
Newly published results from a clinical study of the Diabetes Insulin Guidance System (DIGS-), under development by Hygieia, Inc., demonstrate DIGS' potential to improve blood glucose control for insulin-using patients with type 2 or type 1 diabetes. DIGS automatically adjusted insulin dosage based on each individual's reported blood glucose results.
Soy peptide injection dramatically reduces colon cancer metastasis in mice
After a recent University of Illinois study showed that injection of the soy peptide lunasin dramatically reduced colon cancer metastasis in mice, the researchers were eager to see how making lunasin part of the animals' daily diet would affect the spread of the disease.
FDA grants orphan drug status to NBI-77860 for treatment of congenital adrenal hyperplasia
Neurocrine Biosciences, Inc. announced today that NBI-77860, a proprietary corticotropin releasing factor 1 (CRF) receptor antagonist, has been granted orphan drug status by the United States Food and Drug Administration (FDA) for the treatment of congenital adrenal hyperplasia (CAH) a disease that affects approximately 20,000-30,000 people in the United States.
› Verified 2 days ago